Literature DB >> 23386596

A case-based approach to the practical application of dexmedetomidine in critically ill adults.

Robert MacLaren1, Jill C Krisl, Rebecca E Cochrane, Scott W Mueller.   

Abstract

Dexmedetomidine is a selective α(2) -adrenoceptor agonist that offers unique sedation because patients are readily awakened while administration continues and the drug does not suppress the respiratory center. Limitations of use include higher acquisition cost, inability to produce deep sedation, and bradycardia and hypotension. Using a case-based approach, the purpose of this review was to qualitatively assess the role of dexmedetomidine in the care of the critically ill and in the management of alcohol withdrawal, and to formulate recommendations regarding its clinical application. Sixty-six studies were identified that investigated dexmedetomidine for the provision of sedation. These studies were heterogeneous in design and patient populations; most investigated patients did not require heavy sedation, and few used propofol as the comparator. In general, though, the aggregate results of all studies demonstrate that dexmedetomidine provides comfort, possibly shortens the duration of mechanical ventilation to facilitate extubation, reduces the occurrence of acute brain dysfunction, and facilitates communication, but the drug is associated with hemodynamic instability and requires the supplemental use of traditional sedative and analgesic agents. These outcomes need to be substantiated in additional studies that include assessments of cost-effectiveness. Dexmedetomidine should be considered when patients require mild to moderate levels of sedation of short to intermediate time frames, and they qualify for daily awakenings with traditional sedative therapies. The data for dexmedetomidine in relation to alcohol withdrawal are limited to 12 retrospective reports representing a total of 127 patients. Its role for this indication requires further study, but it may be considered as adjunctive therapy when clinicians are concerned about respiratory suppression associated with escalating doses of γ-aminobutyric acid agonists. Regardless of the indication for dexmedetomidine, the practitioner must closely monitor patient comfort and the occurrence of hemodynamic deviations with the realization that as-needed administration of traditional sedatives and analgesics will be required and some degree of bradycardia and hypotension expected but intervention rarely required.
© 2013 Pharmacotherapy Publications, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23386596     DOI: 10.1002/phar.1175

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  7 in total

1.  Should dexmedetomidine replace benzodiazepines as the preferred sedative, as suggested by new guidelines from the society for critical care medicine?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2013-11

Review 2.  Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research.

Authors:  Andrew J Muzyk; Suzanne Kerns; Scott Brudney; Jane P Gagliardi
Journal:  CNS Drugs       Date:  2013-11       Impact factor: 5.749

3.  The Opioid-Sparing Effect of Perioperative Dexmedetomidine Plus Sufentanil Infusion during Neurosurgery: A Retrospective Study.

Authors:  Shiyu Su; Chunguang Ren; Hongquan Zhang; Zhong Liu; Zongwang Zhang
Journal:  Front Pharmacol       Date:  2016-10-26       Impact factor: 5.810

4.  Effects of dexmedetomidine on sleep quality of patients after surgery without mechanical ventilation in ICU.

Authors:  Weina Lu; Qinghui Fu; Xiaoqian Luo; Shuiqiao Fu; Kai Hu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

5.  Positive Patient Postoperative Outcomes with Pharmacotherapy: A Narrative Review including Perioperative-Specialty Pharmacist Interviews.

Authors:  Richard H Parrish; Heather Monk Bodenstab; Dustin Carneal; Ryan M Cassity; William E Dager; Sara J Hyland; Jenna K Lovely; Alyssa Pollock; Tracy M Sparkes; Siu-Fun Wong
Journal:  J Clin Med       Date:  2022-09-24       Impact factor: 4.964

Review 6.  Interpatient variability in dexmedetomidine response: a survey of the literature.

Authors:  Samantha F Holliday; Sandra L Kane-Gill; Philip E Empey; Mitchell S Buckley; Pamela L Smithburger
Journal:  ScientificWorldJournal       Date:  2014-01-16

7.  Evaluating the transition from dexmedetomidine to clonidine for agitation management in the intensive care unit.

Authors:  Kimberly Terry; Rachel Blum; Paul Szumita
Journal:  SAGE Open Med       Date:  2015-12-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.